The treatment of 124 cases of ulcerative colitis with salazopyrine and attempts of desensibilization in cases of hypersensitiveness to sulfa

Svartz, Nanna

doi:10.1111/j.0954-6820.1948.tb12083.x

Cited by 70 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Mesalamine is the first‐choice drug for treating mild‐to‐moderate ulcerative colitis (UC) 1 . Sulfasalazine (SASP) has been used as the treatment for UC patients since the 1940s 2 . SASP consists of a mesalamine and a sulfapyridine molecule bound by an azo bond, as systemic absorption of sulfapyridine is considered responsible for many of the adverse effects associated with SASP, such as skin rash, a fever, and systemic reactions.…”

Section: Introductionmentioning

confidence: 99%

“…1 Sulfasalazine (SASP) has been used as the treatment for UC patients since the 1940s. 2 SASP consists of a mesalamine and a sulfapyridine molecule bound by an azo bond, as systemic absorption of sulfapyridine is considered responsible for many of the adverse effects associated with SASP, such as skin rash, a fever, and systemic reactions. The incidence of SASP-related adverse events (AEs) was reported to be up to 45%.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Multicenter survey on mesalamine intolerance in patients with ulcerative colitis

Hiraoka

Fujiwara

Toyokawa

et al. 2020

J of Gastro and Hepatol

View full text Add to dashboard Cite

Background and AimAlthough oral mesalamine is the first‐choice drug for treating mild‐to‐moderate ulcerative colitis (UC), some patients show symptoms of intolerance, including exacerbation of diarrhea and abdominal pain. The present study clarified the current state and clinical courses of patients with mesalamine intolerance.MethodsPatients who were diagnosed with UC and administered oral mesalamine at eight hospitals in Japan with a follow‐up period exceeding 1 year were analyzed.ResultsSixty‐seven (11%) of 633 patients showed intolerance to at least one formulation of oral mesalamine. The frequency of mesalamine intolerance has increased in recent years, rising from 5.3% in 2007–2010 to 9.1% in 2011–2013 and 16.2% in 2014–2016. The most common complications were the exacerbation of diarrhea (n = 29), a fever (n = 25), and abdominal pain (n = 22). Readministration of mesalamine/sulfasalazine was attempted in 43 patients, mostly with other types of formulation of mesalamine, and more than half of these patients proved to be tolerant. The risk factors for mesalamine intolerance were female gender (odds ratio [OR] = 1.83; 95% confidence interval [CI], 1.08–3.12), age < 60 years old (OR = 2.82; CI, 1.19–8.33), and pancolitis (OR = 2.09; 95% CI, 1.23–3.60). There were no significant differences in the use of anti‐tumor necrosis factor‐α agents, colectomy, or steroid‐free remission at the last visit between patients with and without mesalamine intolerance.ConclusionsMesalamine intolerance is not rare, and its frequency has been increasing recently. The prognosis of patients with mesalamine intolerance did not differ significantly from that of those without intolerance.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Multicenter survey on mesalamine intolerance in patients with ulcerative colitis

Hiraoka

Fujiwara

Toyokawa

et al. 2020

J of Gastro and Hepatol

View full text Add to dashboard Cite

show abstract

“…There are several established examples in which the mechanism of action of the drug has not been fully characterized, and in which multiple off-target responses may be expected. Such drugs include sulfasalazine, which has been used for the treatment of ulcerative colitis since the 1940s (72) and which has been shown to inhibit both IKK␣ and IKK␤ (79). This phenomenon is not, however, limited to established drugs with imprecisely defined molecular effects; drugs developed in the precision medicine era also have diverse effects on NF-B signaling.…”

Section: Potential For Alternative Pathway Nf-b Signaling As a Therapmentioning

confidence: 99%

Importance of the alternative NF-κB activation pathway in inflammation-associated gastrointestinal carcinogenesis

Merga

O’Hara

Burkitt

et al. 2016

American Journal of Physiology-Gastrointestinal and Liver Physi

View full text Add to dashboard Cite

Chronic inflammation is a common factor in the development of many gastrointestinal malignancies. Examples include inflammatory bowel disease predisposing to colorectal cancer, Barrett's esophagus as a precursor of esophageal adenocarcinoma, and Helicobacter pylori-induced gastric cancer. The classical activation pathway of NF-κB signaling has been identified as regulating several sporadic and inflammation-associated gastrointestinal tract malignancies. Emerging evidence suggests that the alternative NF-κB signaling pathway also exerts a distinct influence on these processes. This review brings together current knowledge of the role of the alternative NF-κB signaling pathway in the gastrointestinal tract, with a particular emphasis on inflammation-associated cancer development.

show abstract

“…5-aminosalicylate acid (5-ASA)-based compounds have remained the mainstay of treatment for patients with UC since the 1940s. The prototypical agent sulfasalazine, developed by the rheumatologist Nana Swartz, was shown to be effective in treating active UC [2,3]. However, owing to the occurrence of side effects in 20-30% of patients [4], an alternative to sulfasalazine was sought.…”

Section: Drug Profilementioning

confidence: 99%

Once-daily mesalamine granules for ulcerative colitis

Lawlor¹,

Ahmed²,

Moss³

2010

Expert Review of Clinical Immunology

View full text Add to dashboard Cite

Mesalamine extended-release capsules (Apriso [Salix Pharmaceuticals, Raleigh, NC, USA]) are the first once-daily mesalamine preparation approved by the US FDA for the maintenance of remission of ulcerative colitis (UC). Each mesalamine extended-release capsule contains granules of a mesalamine-polymer matrix that are coated with a pH-sensitive resin. This design begins releasing mesalamine (0.375 g) once the pH is more than 6 in the ileum and colon. Two clinical trials have reported that mesalamine extended-release capsules (1.5 g/day) maintained remission in 79% of patients with UC who were in clinical remission. Reported adherence with mesalamine extended-release capsules once daily was high (>90%) in these studies. This article examines the efficacy and safety of mesalamine extended-release capsules in the maintenance of remission in patients with UC.

show abstract

The treatment of 124 cases of ulcerative colitis with salazopyrine and attempts of desensibilization in cases of hypersensitiveness to sulfa

Cited by 70 publications

References 0 publications

Multicenter survey on mesalamine intolerance in patients with ulcerative colitis

Multicenter survey on mesalamine intolerance in patients with ulcerative colitis

Importance of the alternative NF-κB activation pathway in inflammation-associated gastrointestinal carcinogenesis

Once-daily mesalamine granules for ulcerative colitis

Contact Info

Product

Resources

About